Linked Life Data

8669879

Source:http://linkedlifedata.com/resource/pubmed/id/8669879

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6B
pubmed:dateCreated
1996-8-7
pubmed:abstractText
A sensitive and relatively specific tumoral marker for lung epidermoid carcinomas could be used to identify patients likely to benefit from new therapeutic protocols. The cyfra 21-1 fragment of cytokeratin 19 has raised much hope in this regard amongst both technologists and clinicians. In a study of 195 subjects, we have shown by means of a serum assay that the usual cut-off value for this marker (3.3 ng/ml) can be lowered to 1.5 ng/ml without loss of specificity, and with an increase in sensitivity. There was a good correlation between serum marker level and tumor extension, but though cyfra 21-1 was not predictive of the suitability of a patient for surgery. A decrease of cyfra-21-1 was observed after complete resection of the tumor. There was no relation between serum assay results and immunohistochemical findings.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2857-63
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients.
pubmed:affiliation
Centre de Lutte Contre le Cancer Eugène Marquis, Département de Biologie Clinique et Expérimentale, Rennes, France.
pubmed:publicationType
Journal Article, Comparative Study